FDA approves AI-based breast cancer screening software MammoScreen®

November 29, 2021
Sales and Marketing

The FDA has approved MammoScreen®, Therapixel’s explainable and actionable Artificial Intelligence (AI) based software assisting Radiologists in breast cancer screening. …

New COVID-19 variant in South Africa as massive surge in Europe infections

November 26, 2021
Medical Communications

A new variant of coronavirus found in South Africa is feared to be more transmissible than other strains, and poses …

Allorion gains $40 million funding to enhance and discover precision targets

November 26, 2021
Medical Communications

Allorion Therapeutics has announced that they have gained $40 million in Series A financing. The funding was led by Chinese …

US government expands COVID-19 booster eligibility ahead of holidays

November 25, 2021
Business Services

The Biden administration has expanded COVID-19 booster eligibility, and millions of Americans have received their booster shots at a near …

Groundbreaking success shown in target drug combination for aggressive brain tumours

November 25, 2021
Business Services

A combination of two targeted cancer drugs have shown unprecedented activity in patients with highly malignant brain tumours carrying a …

FDA approve first therapy to treat ultra-rare cancer

November 24, 2021
Research and Development

Aadi Bioscience announced that the FDA have approved the intravenous drug Fyarro (sirolimus protein-bound particles for injectable suspension) for the …

Ocuphire announces beginning of Phase III trial of treatment for reversal of mydriasis (RM)

November 24, 2021
Research and Development

Ocuphire Pharma, a clinical-stage ophthalmic biopharmaceutical company, announced that the first subjects have been enrolled in the MIRA-3 Phase III …

FDA approves Livtencity as first treatment for drug-resistant post-transplant infection

November 24, 2021
Manufacturing and Production, Research and Development

The FDA have approved Livtencity (maribavir) as the first drug for treating adults and pediatric patients with a common type …

HUTCHMED and AstraZeneca begin Phase III trial of lung cancer treatment

November 24, 2021
Research and Development

HUTCHMED Limited and AstraZeneca have initiated SACHI, a China Phase III study of Savolitinib (ORPATHYS®), an oral, potent, and highly …

Santhera and ReveraGen announce positive results from VISION-DMD study

November 23, 2021
Manufacturing and Production

Santhera Pharmaceuticals and ReveraGen BioPharma have announced new topline results after completion of the VISION-DMD study at week 48.

Sterling Pharma Solutions announces £10m investment to increase manufacturing capacity

November 23, 2021
Manufacturing and Production

Contract development and manufacturing organisation Sterling Pharma Solutions has announced a £10m multi-year investment strategy for its site in Dudley, …

European Commission approves BYANNLI for management of schizophrenia in adults

November 23, 2021
Manufacturing and Production

Johnson & Johnson have announced the approval of the long-acting atypical antipsychotic therapy BYANNLI® by the European Commission (EC), for …

Breakthrough personalised T-cell therapy for children with brain tumours

November 23, 2021
Manufacturing and Production

The Centre for Cancer and Immunology Research, Children’s National Research Institute, have developed a new approach that identifies unique proteins …

FDA approves Pfizer and Moderna boosters for all US adults

November 22, 2021
Sales and Marketing

The FDA and CDC have cleared the Pfizer and Moderna booster jabs for adults, after reviewing new data supporting the …

FDA accept New Drug Application for Obseva’s linzagolix

November 22, 2021
Sales and Marketing

Obseva, a biopharmaceutical company developing and commercialising novel therapies to improve reproductive health, have announced that the NDA for linzagolix …

Novel mechanisms could transform standards of care in multiple cancers, MS, and Lupus

November 22, 2021
Sales and Marketing

Leading science and technology company, Merck KGaA, Darmstadt, Germany have identified five mid- to late-stage assets with first-in-class potential for …

Scientists uncover factors influencing waning immunity with Pfizer COVID-19 vaccine

November 22, 2021
Sales and Marketing

Scientists have discovered multiple factors influencing declining immunity over time with the Pfizer COVID-19 vaccine, according to News Medical.

Pfizer seek EUA for novel COVID treatment pill

November 19, 2021
Medical Communications

Pfizer is seeking FDA Emergency Use Authorisation (EUA) for the novel oral antiviral, Paxlovid. The pill, if authorised, will help …

ImmunityBio expands COVID-19 vaccine programme to incorporate ‘mix-and-match’ technologies

November 19, 2021
Medical Communications

Clinical-stage immunotherapy company, ImmunityBio Inc, has announced the expansion of the company’s cancer and infectious disease vaccine programmes to include …

FDA approve Keytruda as adjuvant treatment for kidney cancer

November 19, 2021
Medical Communications

The FDA has approved Keytruda® for the treatment of patients with early renal cell carcinoma at high or intermediate-high risk …

The Gateway to Local Adoption Series

Latest content